India's semaglutide access rules may exclude those most in need due to mismatched health metrics
Original framing: “Opinion: Semaglutide is going off-patent in India. But will people who need it be able to get it?” — STAT News
The article is grounded in scientific critique of the limitations of BMI and cardiovascular risk metrics in non-Western populations. It references the scientific basis for questioning these metrics and their implications for equitable drug access, though it does not delve into specific alternative scientific models.
The article reveals how global health metrics, when applied uncritically in India, can exclude those most in need of treatment.
This reflects a historical pattern of Western medical paradigms shaping health policy in the Global South, often at the expense of local physiological and cultural realities. The scientific critique of BMI and cardiovascular risk metrics underscores the need for cross-cultural adaptation in health frameworks. While the article lacks Indigenous or spiritual perspectives, it highlights the marginalization of Indian patients and the systemic failure to include diverse voices in health policy. Future health modeling must incorporate inclusive, culturally responsive metrics and participatory design to ensure equitable access. By integrating scientific rigor with cross-cultural wisdom and local innovation, India can move toward a more just and effective healthcare system.